The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators

Stephanie Binder; Michela Luciano; Jutta Horejs-Hoeck

doi:10.1016/j.cytogfr.2018.08.004

The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators

Cytokine Growth Factor Rev. 2018 Oct:43:8-15. doi: 10.1016/j.cytogfr.2018.08.004. Epub 2018 Aug 29.

Authors

Stephanie Binder¹, Michela Luciano¹, Jutta Horejs-Hoeck²

Affiliations

¹ University of Salzburg, Department of Biosciences, Hellbrunner Str. 34, Salzburg, Austria.
² University of Salzburg, Department of Biosciences, Hellbrunner Str. 34, Salzburg, Austria. Electronic address: jutta.horejs_hoeck@sbg.ac.at.

PMID: 30181021
DOI: 10.1016/j.cytogfr.2018.08.004

Abstract

Cytokines exert profound effects on the progression of hematopoietic malignancies such as acute myeloid leukemia (AML). Critical roles of cytokines in the context of inflammation have gained special interest. While pro-inflammatory mediators such as IL-1β, TNF-α and IL-6 tend to increase AML aggressiveness, anti-inflammatory mediators such as TGF-β and IL-10 appear to impede AML progression. Dysregulation of the complex interactions between pro- and anti-inflammatory cytokines in AML may create a pro-tumorigenic microenvironment with effects on leukemic cell proliferation, survival and drug-resistance. This article summarizes current knowledge about the functions of pro- and anti-inflammatory cytokines in AML, their modes of action, and therapeutic interventions with potential to improve clinical outcomes for AML patients.

Keywords: Acute myeloid leukemia (AML); IL-10; IL-1Ra; IL-1β; IL-35; IL-6; TGFβ.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cytokines / immunology*
Humans
Inflammation Mediators / immunology*
Leukemia, Myeloid, Acute / immunology*
T-Lymphocytes / immunology

Substances

Cytokines
Inflammation Mediators